UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

      X    QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE    SECURITIES
           EXCHANGE ACT OF 1934

               For the quarterly period ended December 31, 2005

           _ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934
                        For the transition period from to
                        Commission File Number 000-24541

                          CORGENIX MEDICAL CORPORATION
                 (Name of Small Business Issuer in its Charter)

              Nevada                           93-1223466
  (State or other jurisdiction of    (I.R.S. Employer Identification
  incorporation or organization)                  No.)


                12061 Tejon Street, Westminster, Colorado 80234

         (Address of principal executive offices, including zip code)

                                 (303) 457-4345


               (Issuer's telephone number, including area code)


      (Former  name,  former  address and former  fiscal year, if changed since
      last report)


Check  whether  the  issuer:  (1) filed  all  reports  required  to be filed by
Section  13 or 15(d) of the  Exchange  Act  during  the past 12 months  (or for
such shorter  period that the  registrant  was required to file such  reports),
and  (2)  has  been  subject  to  such  filing  requirements  for  the  past 90
days.     Yes X   No  ___
              -


Indicate by check mark whether the  registrant  is a shell  company (as defined
in Rule 12b-2 of the Exchange Act)     Yes _     No   X
                                                      -


The number of shares of Common Stock outstanding was 9,888,884 as of February
14, 2006.


Transitional Small Business Disclosure Format.     Yes _     No   X
                                                                  -

<PAGE>



                                        3
                                        2
                          CORGENIX MEDICAL CORPORATION


                                December 31, 2005





                                TABLE OF CONTENTS


                                                                        Page


                                     Part I


                              Financial Information


      Item 1.   Consolidated Financial Statements                          3


      Item 2.   Management's Discussion and Analysis or Plan of Operation 17


      Item 3.  Controls and Procedures                                    21




                                     Part II


                                Other Information


      Item 1.   Legal Proceedings                                         26


      Item 2.   Changes in Securities and Use of Proceeds                 26


      Item 3.   Defaults Upon Senior Securities                           26


      Item 4.   Submission of Matters to a Vote of Security Holders       26


      Item 5.   Other Information                                         26


      Item 6.   Exhibits and Reports on Form 8-K                          26


      Certifications                                                      28


      Signature Page                                                      31







<PAGE>



                                     PART I
                   Item 1. Consolidated Financial Statements
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                           Consolidated Balance Sheets

-------------------------------------------------------------------------------

                                                  December 31,   June 30, 2005
                                                     2005
                                                 (Unaudited)
                     Assets

Current Assets:
   Cash and equivalents                           $ 2,108,280      1,281,965
   Accounts receivable, less allowance for          1,078,262        887,645
    doubtful accounts of  $30,097
   Inventories                                      1,359,528      1,215,787
   Prepaid expenses                                    40,631         51,842
                                                  ----------------------------

                    Total current assets            4,586,701      3,437,239

Equipment:
   Capitalized software costs                         122,855        122,855
   Machinery and laboratory equipment                 657,596        639,692
   Furniture, fixtures, leaseholds and office         533,000        523,762
equipment                                         ---------------------------
                                                    1,313,451      1,286,309
   Accumulated depreciation and amortization       (1,075,332)    (1,028,103)
                                                  ---------------------------

                  Net equipment                       238,119        258,206
                                                  ---------------------------

Intangible assets:
   Patents, net of accumulated amortization of
    $1,117,544  and $1,093,970                           -            23,574
   License                                             18,275         18,275
                                                  ---------------------------
                     Net intangible assets             18,275         41,849
   Other assets:
   Deferred financing costs net of amortization     1,362,836        907,095
of  $201,374 and $39,440
   Due from officer                                    12,000         12,000
   Restricted cash                                  2,250,000        250,000
   Other assets                                        80,736         86,105
                                                  ---------------------------

                     Total assets                  $8,548,667      4,992,494
                                                  ===========================


      Liabilities and Stockholders' Equity

Current liabilities:
   Current portion of notes payable, net of        $  507,414       221,176
discount
   Current portion of capital lease obligations        17,351        22,370
   Accounts payable                                   232,823       453,764
   Accrued payroll and related liabilities            240,149       218,411
   Accrued interest                                    22,593           753
   Accrued liabilities                                 41,739       113,293
                                                  ----------------------------

                       Total current liabilities   1,062,069      1,029,767

Notes payable, net of discount, less current       1,194,440        980,716
portion
Capital lease obligations, less current portion       14,441         22,754
                                                  ----------------------------

                       Total liabilities           2,270,950      2,033,237
                                                  ----------------------------
Redeemable common stock, 880,282 shares issued
   and outstanding, aggregate redemption value
   of $500,000, net of redeemable stock subject
   to redemption via payments on related note
   payable, of $250,000 at December 31, 2005
   (note 5)                                          250,000        500,000

Redeemable preferred stock, 2,000,000 shares
   issued and outstanding at December 31, 2005
   (note 1)                                         2,000,000          -

Stockholders' equity:
   Common stock, $0.001 par value.  Authorized
   40,000,000 shares; issued and outstanding
   9,375,305 and 8,172,435 shares at December 31
   and June 30, respectively                            8,495         7,292
   Additional paid-in-capital                       9,919,499     7,966,172
   Accumulated deficit                             (5,885,779)   (5,501,144)
   Accumulated other comprehensive loss               (14,498)      (13,063)
                                                  ----------------------------

                          Total stockholders'
                           equity                   4,027,717     2,459,257
                                                  ----------------------------
                         Total liabilities and
                         stockholders' equity      $8,548,667     2,847,824
                                                 =============================
See accompanying notes to consolidated financial statements.



<PAGE>


                            CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
        Consolidated Statements of Operations and Comprehensive Income

                            Three Months Ended             Six Months Ended
                          December 31,  December 31,   December 31, December 31,
                            2005          2004             2005       2004

                            ---------------------------------------------------
                                  (Unaudited)                 (Unaudited)
Net sales                $1,580,883    $1,276,571     $3,215,836    $2,579,642
Cost of sales               577,592       451,051      1,159,458     1,008,273
                            --------------------------------------------------

          Gross profit    1,003,291       825,520      2,056,378    1,571,369


Operating expenses:
   Selling and marketing    365,714       368,538        746,426      744,476

   Research and development 153,246       138,887        281,756      295,445

   General and
   administrative           400,412       334,192        730,515      633,541
                            ---------------------------------------------------

         Total expenses     919,372       841,617      1,758,697    1,673,462


         Operating income
         (loss)              83,919       (16,097)       297,681     (102,093)

Interest expense, net       344,446        85,941        682,316      190,144

                            ---------------------------------------------------

          Net loss         (260,527)     (102,038)      (384,635)    (292,237)


 Accretion of discount on
   redeemable common stock     -           21,639           -         43,278

                            ---------------------------------------------------

Net loss available to
   common stockholders    $(260,527)    $(123,677)     $(384,635)   $(335,515)

Net loss per share, basic
   and diluted            $   (0.03)        (0.02)         (0.04)       (0.06)

Weighted average shares
   outstanding, basci and
   diluted (note 2)       9,023,495      5,337,058     8,701,274    5,330,938
                          =========      =========     =========    =========

          Net loss        $(260,527)      (102,038)     (384,635)    (292,237)


Other comprehensive
loss-foreign currency
translation loss             (1,123)        (3,527)       (1,435)      (5,346)
                            --------       --------      --------      --------

 Total comprehensive loss $(261,650)      (105,565)     (386,070)    (297,583)
                          ==========      =========     =========    ==========
See accompanying notes to consolidated financial statements.

<PAGE>


                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                 Consolidated Statement of Stockholders' Equity
                   For the six months ended December 31, 2005
                                   (unaudited)
         Common      Common                          Accumulated
         Stock,      Stock, Additional                 other         Total
         Number     $0.001   paid-in    Accumulated comprehensive  stockholders'
       of Shares     par     capital      deficit      loss         equity
           --------------------------------------------------------------------

Balance at
June
30, 2005  8,172,435 $7,292 $7,966,172  $(5,501,144)   (13,063)    $2,459,257

Issuance
of common
stock for
services   280,744     281     59,429                                59,710
Issuance
 of warrants
 for financing
 costs                        360,969                               360,969
Issuance of
 common stock
 in exchange
 for debt and
 interest  529,388     529    158,287                               158,816
Beneficial
 conversion
 feature of
 institutional
 convertible
 note payable               1,363,635                             1,363,635
Exercise of
 warrants  382,738     383      6,517                                 6,900
Exercise of
 stock
 options    10,000      10      4,490                                   4,500
Foreign currency
translation                                          (1,435)       (1,435)
Net loss                                   (384,635)               (384,635)
              -----------------------------------------------------------------

Balance at
December 31,
2005      9,375,305 $  8,495 $ 9,919,499 $(5,885,779) $(14,498) $ 4,027,717

See accompanying notes to consolidated financial statements.



<PAGE>




                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES


                      Consolidated Statements of Cash Flows
-------------------------------------------------------------------------------

                                                   Six Months Ended
                                               December 31,    December 31,
                                                 2005              2004
                                               ------------------------------
                                                      (Unaudited)
Cash flows from operating activities:
  Net loss                                     $(384,635)         (292,237)
  Adjustments to reconcile net loss to
 net cash provided by
 (used in) operating
 activities:
       Depreciation and amortization              71,869           94,033
       Accretion of discount on notes payable    382,796          148,127
       Common stock issued for services           59,710            5,120
       Common stock issued for interest           45,982              -
       Amortization of deferred
          financing costs                        161,934              -
       Changes in operating
       assets and liabilities
             Accounts receivable, net           (206,315)          71,718
             Inventories                        (145,539)        (163,098)
             Prepaid expenses and
              other assets, net of warrants
              issued for finance costs          (241,371)         (6,489)
                 Accounts payable                (199,318)        213,675
                 Accrued payroll and
                  related liabilities              20,515           5,963
                 Accrued liabilities,
                  including accrued interest      (47,937)         15,131
                                               -------------------------------
                 Net cash provided by
                   (used in) operating
                   activities                   (482,309)         91,943

                                               -------------------------------

Cash flows used in investing activities:
   Purchases of equipment                         (28,867)       (12,635)
                                               --------------------------------

Cash flows from financing activities:
  Proceeds from issuance of preferred stock     2,000,000            -
  Proceeds from exercise of stock options           4,500            -
  Proceeds from exercise of warrants                6,900            -
  Proceeds from issuance of notes
    payable, net of original issue discout      1,363,635            -
  Proceeds from preferred stock deposited
    in escrow                                   (2,000,000)            -
  Payments on notes payable                       (20,000)        (100,283)
  Payments on capital lease obligations           (13,332)         (30,760)
                                               --------------------------------

           Net cash (used in) provided
             by financing activities            1,341,703         (131,043)
                                               --------------------------------

           Net increase (decrease) in
             cash and cash equivalents            830,527          (51,735)


Impact of exchange rate on cash                    (4,213)           8,076

Cash and cash equivalents at beginning
of period                                        1,281,966         468,954
                                               --------------------------------
Cash and cash equivalents at end of
period                                         $ 2,108,280         425,295
                                               ================================

Supplemental cash flow disclosures:
  Cash paid for interest                       $    84,241          25,179
                                               --------------------------------
Noncash investing and financing
activity--
    Equipment acquired under capital leases    $     -               45,400
                                               --------------------------------
    Issuance of stock for debt                 $  112,834               -
    Placement warrants issued in
       connection with financings              $  360,969               -
    Conversion of redeemable common
       stock to note payable                   $  250,000               -
                                               --------------------------------
See accompanying notes to consolidated financial statements.


<PAGE>


                 CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.        DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

      Corgenix Medical Corporation ("Corgenix" or the "Company") is engaged in
  the research, development, manufacture, and marketing of in vitro (outside the
  body) diagnostic products for use in disease detection and prevention. We
  currently sell 51 diagnostic products on a worldwide basis to hospitals,
  clinical laboratories, commercial reference laboratories, and research
  institutions.

  Our corporate headquarters is located in Westminster, Colorado. We have two
  wholly owned operating subsidiaries:

o     Corgenix,  Inc.,  ("Corgenix,  Inc.") (formerly  REAADS),  established in
           1990  and  located  in  Westminster,  Colorado.  Corgenix,  Inc.  is
           responsible  for sales and marketing  activities  for North America,
           and also conducts product development,  product support,  regulatory
           affairs and product manufacturing of the diagnostic products.

o          Corgenix (UK) Ltd., ("Corgenix UK"), incorporated in the United
           Kingdom in 1996 (formerly REAADS Bio-Medical Products (UK) Limited),
           is located in Peterborough, England. Corgenix UK manages the
           diagnostic products business' international sales and marketing
           activities except for distribution in North America, which is under
           the responsibility of Corgenix, Inc.

  We continue to use the REAADS trademark and trade name in the sale of products
  that we manufacture.

Recent Developments

      Corgenix entered into agreements on December 28, 2005 to complete two
separate private placement financings with certain institutional and other
accredited investors.

      The first financing was a private placement to Barron Partners, L.P., or
Barron, a New York based private partnership, consisting of two million shares
of Series A Convertible Preferred Stock. The shares of Series A Convertible
Preferred Stock were sold at $1.00 per share for gross proceeds of $2,000,000.
The shares of preferred stock are convertible initially into 2.8571428571 shares
of the Company's common stock. In addition, Corgenix issued warrants to Barron
to acquire up to an additional 15,000,000 shares of Corgenix common stock, of
which 5,000,000 are exercisable at $0.40 per share, 5,000,000 are exercisable at
$0.50, and 5,000,000 are exercisable at $0.60. The warrants are exercisable for
five years from the date of issuance.

      The exercise prices of the warrants, and the conversion rate and price of
the shares of preferred stock, are subject to adjustment upon the occurrence of
certain specified events, including issuance of additional shares of common
stock or subdivision or combining of shares of common stock.

      The conversion right as contained in the preferred stock certificate of
designations and the exercise rights contained in the warrants provide that a
holder will not convert an amount of preferred stock or exercise warrants to the
extent that the number of shares held by the holder, when added to the number of
shares of common stock beneficially owned by such holder or issuable if the
holder exercised one or more of its warrants immediately prior to conversion,
would exceed 4.9% of the Company's issued and outstanding common stock.

      The transaction with Barron also included a Registration Rights Agreement
in which the Company has agreed to file a registration statement on Form SB-2
covering the shares of common stock issuable upon the exercise of the warrants
or the conversion of the preferred stock. If the registration statement is not
declared effective or is otherwise ineffective or incomplete on the time
schedule cited in the Registration Rights Agreement, the Company shall pay the
holders of the preferred stock or warrants liquidated damages in the amount of
30,000 shares of preferred stock. However, in no event will the Company be
required to pay any liquidated damages in an amount exceeding, together with any
other adjustments, 14% of the number of shares of preferred stock originally
issued to Barron.

      At the closing, the Company reimbursed Barron $15,000 for due diligence
expenses. In addition, Ascendiant Securities, LLC acted as a financial advisor
to the Company. As compensation for its services, the Company will pay to
Ascendiant a success fee equal to 8% of the initial gross proceeds ($160,000),
which fee would be paid from escrow if and when those funds are released to
Corgenix from escrow. If funds are not released to Corgenix, then no cash fee
will be paid to Ascendiant. If and when the Barron warrants are exercised, then
Corgenix would pay Ascendiant 8% of those gross proceeds. Three warrants were
issued to Ascendiant, each for the purchase of up to 552,380 shares, or 8% of
the securities issued in the transaction, at $.40, $.50, and $.60 with net
exercise rights.

      As currently constituted, the Company has 40 million shares of common
stock authorized, of which approximately 9.3 million shares are issued and
outstanding, and approximately 30.7 million are reserved for issuance to
accommodate the exercise or conversion of warrants, options, and convertible
debt that is currently outstanding. If all of the shares of preferred stock and
warrants issued to Barron in the recent financing were converted or exercised
today, then approximately 20.7 million shares of common stock would be needed to
satisfy such activity.

      The Company does not currently have enough shares of common stock
authorized to satisfy the exercise of the warrants or conversion of the
preferred stock issued to Barron. As a result, the $2,000,000 in gross proceeds
from Barron have been placed into an escrow account, and will be released to
Corgenix if the shareholders of the Company approve an amendment to the
Company's articles of incorporation increasing the authorized common shares. To
that end, the Company has filed a proxy statement calling a special meeting of
the shareholders of the Company on March 24, 2006, to vote upon an amendment to
the Articles increasing the number of authorized shares of Common Stock from the
current 40 million to 100 million (the "Share Increase Amendment"). If by July
1, 2006, the Share Increase Amendment has not been adopted or approved by the
Company's shareholders, then the escrow agent would be instructed to return the
$2,000,000 in escrow funds to Barron, the preferred stock certificates would be
canceled, and the Company would be obligated to pay Barron an amount equal to
one percent (1%) of the escrow funds, or $20,000, for each thirty (30) day
period during which the funds were held in escrow. If the Share Increase
Amendment is adopted or approved by the Company's shareholders before July 1,
2006, then the $2,000,000 plus accrued interest would be released to the
Company, and the preferred stock certificates would be issued from escrow to
Barron.

      If the Share Increase Amendment were adopted or approved by the Company's
shareholders, then Company will immediately reserve and keep available shares of
common stock for the purpose of enabling the Company to issue the shares of
common stock underlying the preferred stock and warrants issued to Barron.

      With the Barron funding described above, if the funds are released from
escrow, the Company plans to use the net proceeds, after transaction fees and
expenses, for key strategic initiatives, working capital and other general
corporate purposes.

      Corgenix granted to Barron the right to participate in any subsequent
financings by the Company on a pro rata basis at one hundred percent (100%) of
the offering price; provided that any such right to participate shall be
effective if and only if the right of first refusal in favor of the Company's
current convertible debt investors has not been exercised.

      If the funds in escrow are released to the Company prior to June 30, 2006
due to shareholder approval of the Share Increase Amendment, and if the
Company's EBITDA for the audited fiscal year ended June 30, 2006, as calculated
based upon the audited financial statements filed with the Company's Form 10-KSB
filed with the Securities and Exchange Commission, is less than $1,150,000, then
the Company must issue to Barron such number of additional shares of preferred
stock equal to 2,000,000 multiplied by the percentage by which EBITDA is less
than $1,150,000, expressed as a positive number; provided that in no event will
the number of additional shares of preferred stock issued due to this EBITDA
adjustment exceed 14% of the number of shares of Preferred Stock originally
issued to Barron, or 280,000 shares. For example if EBITDA is $920,000 (20%
decline) then the Company would issue to the Investor an additional 14% (i.e.
280,000) shares of preferred stock; provided that at the time Barron continues
to hold all 2,000,000 shares of preferred stock originally issue on the Closing.
EBITDA is defined in the Preferred Stock Purchase Agreement as net income of the
Company, before interest, taxes, depreciation, amortization and one time
charges, including, but not limited to, loss on the extinguishment of debt.

      The Company has agreed to ensure that a majority of the members of the
board of directors, and a majority of the compensation and audit committees, are
qualified independent directors, as defined by the NASD, within 90 days after
December 28, 2005. If the board fails to meet either the majority board or
majority committee requirement, then in each instance the Company will pay to
Barron $20,000 for each month during which this requirement has not been met,
which may be paid, at the Company's election, in cash or additional shares of
preferred stock.

      The foregoing is a summary of the terms of the Barron Preferred Stock
Purchase Agreement, the Barron Common Stock Purchase Warrants, the Barron
Registration Rights Agreement, the Barron Escrow Agreement, and the Barron
Lockup Agreements. Such summary does not purport to be complete and is qualified
in its entirety by reference to the full text of each such agreement, copies of
which are attached hereto and incorporated herein by reference.

      The second financing, also completed on December 28, 2005, was a private
placement financing with certain institutional and other accredited investors
that had previously invested in the Company, including Truk International Fund,
LP, Truk Opportunity Fund, LLC and CAMOFI Master LDC (f/k/a DCOFI Master LDC),
representing net proceeds to the Company of $1,363,635. This financing was made
pursuant to the exercise of an additional investment right by such institutional
investors that was granted to them pursuant to a financing on substantially
similar terms completed on May 19, 2005.

      This private placement includes $1,500,000 in aggregate principal amount
of Secured Convertible Term Notes due 2008. Warrants to acquire approximately
3,800,000 shares of the Company's common stock, at $0.23 per share, were also
issued to the investors (the AIR Warrants).

      The interest rate on the Secured Convertible Term Notes is the greater of
(i) prime rate plus 3% or (ii) 12%, except for the portion of the note proceeds
that is held in the restricted cash account, which amount accrues interest at
the prime rate. However, (i) if the Company has registered the shares of common
stock underlying the Secured Convertible Term Notes and the AIR Warrants, and
that registration is declared effective, and (ii) the market price of the common
stock for the five consecutive trading days preceding the last business day of
each month exceeds the conversion price (as adjusted) by 25%, then the interest
rate for the next calendar month is reduced by 25 basis points for each
incremental 25% increase in the market price above the fixed conversion price.

      Amortizing payments of the principal amount begin on June 1, 2006 and such
payments are due on the first day of each month thereafter until the maturity
date in December 2008, at which time any outstanding principal shall be due and
payable. Interest payments begin January 1, 2006, and such interest payments are
due on the first day of each subsequent month until the principal amount is paid
in full.

      The Secured Convertible Term Notes may be prepaid, but any prepayment must
be 125% of the portion of the principal amount to be prepaid, together with
accrued but unpaid interest thereon and any other sums due. The holders of the
Secured Convertible Term Notes may accelerate all sums of principal, interest
and other fees then remaining unpaid upon the occurrence of an event of default
(as defined in the Secured Convertible Term Notes) beyond any applicable grace
period. In the event of such acceleration, the amount due and owing the holder
shall be 125% of the outstanding principal amount (plus accrued and unpaid
interest and fees, if any). As part of the financing terms, a blanket lien filed
in connection with the May 19, 2005 financing covering all of the Company's
assets extends to this financing.

      The number of shares of common stock to be issued upon conversion of a
Secured Convertible Term Note is determined by dividing that portion of the
principal amount, interest and fees to be converted by the then applicable
conversion price, which is initially set at $0.30. The conversion price may be
adjusted to account for certain events, such as stock splits, combinations,
dividends and share issuances below the then current conversion price.

      The conversion right as contained in the Secured Convertible Term Notes
provide that a holder will not convert an amount of a Note that would be
convertible into shares of common stock to the extent that the number of shares
held by the holder, when added to the number of shares of common stock
beneficially owned by such holder or issuable if the holder exercised one or
more of its AIR Warrants immediately prior to conversion, would exceed 4.99% of
the Company's issued and outstanding common stock.

      The Company also issued AIR Warrants to acquire approximately 3,800,000
shares of the Company's common stock. The AIR Warrants are exercisable for seven
years from the date of issuance at an exercise price of $0.23 per share. The
exercise price is also subject to adjustment upon the occurrence of certain
specified events, including issuance of additional shares of common stock or
subdivision or combining of shares of common stock.

      The transaction also included a Registration Rights Agreement in which the
Company has agreed to file a registration statement on Form SB-2 covering the
shares of common stock issuable upon the exercise of the AIR Warrants and the
conversion of the Secured Convertible Term Notes. If the registration statement
is declared effective or is otherwise ineffective or incomplete on the time
schedule cited in the Registration Rights Agreement, the Company shall pay the
holders of the Secured Convertible Term Notes or AIR Warrants liquidated damages
in the amount of 1.5% on the original principal amount of Secured Convertible
Term Notes for each 30-day period that elapses until the registration statement
is declared effective.

      Our Business

           Introduction

      Our business includes the research, development, manufacture, and
marketing of in vitro diagnostic products for use in disease detection and
prevention. We sell 51 diagnostic products on a worldwide basis to hospitals,
clinical testing laboratories, universities, biotechnology and pharmaceutical
companies and research institutions. We have developed and we manufacture most
of our products at our Colorado facility, and we purchase what we refer to as OM
Products from other healthcare manufacturers for resale by us. All of these
products are used in clinical laboratories for the diagnosis and/or monitoring
of three important areas of health care:

o       Autoimmune disease (diseases in which an individual creates antibodies
        to one's self, for example systemic lupus erythematosus ("SLE") and
        rheumatoid arthritis ("RA");

o       Vascular disease (diseases associated with certain types of thrombosis
        or clot formation, for example antiphospholipid syndrome, deep vein
        thrombosis, stroke and coronary occlusion); and

o Liver diseases (fibrosis, cirrhosis and transplanted organ rejection).

      In addition to our current products, we are actively developing new
laboratory tests in other important diagnostic testing areas. See "-- Other
Strategic Relationships." We manufacture and market to clinical laboratories and
other testing sites worldwide. Our customers include large and emerging health
care companies such as Instrumentation Laboratories, Helena Laboratories and
Diagnostic Grifols, S.A.

      Most of our products are based on our patented and proprietary application
of Enzyme Linked ImmunoSorbent Assay or ELISA technology, a clinical testing
methodology commonly used worldwide. Most of our current products are based on
this platform technology in a delivery format convenient for clinical testing
laboratories. The delivery format, which is referred to as "Microplate," allows
the testing of up to 96 samples per plate, and is one of the most commonly used
formats, employing conventional testing equipment found in virtually all
clinical laboratories. The availability and broad acceptance of ELISA Microplate
products reduces entry barriers worldwide for our new products that employ this
technology and delivery format. Our products are sold as "test kits" that
include all of the materials required to perform the test, except for routine
laboratory chemicals and instrumentation. A test using ELISA technology involves
a series of reagent additions into the Microplate, triggering a complex
immunological reaction in which a resulting color occurs. The amount of color
developed in the final step of the test is directly proportional to the amount
of the specific marker being tested for in the patient or unknown sample. The
amount of color is measured and the results calculated using routine laboratory
instrumentation. Our technology specifies a process by which biological
materials are attached to the fixed surface of a diagnostic test platform.
Products developed using this unique attachment method typically demonstrate a
more uniform and stable molecular configuration, providing a longer average
shelf life, increased accuracy and superior specificity than the products of our
competitors.

      Some of the OM products which we obtain from other manufacturers and sell
through our distribution network utilize technologies other than our patented
and proprietary ELISA technology.

      Our diagnostic tests are intended to aid in the identification of the
causes of illness and disease, enabling a physician to select appropriate
patient therapy.

      Internally and through collaborative arrangements, we are developing
additional products that are intended to broaden the range of applications for
our existing products and to result in the introduction of new products.

      Since 1990, our sales force and distribution partners have sold over 12
million tests worldwide under the REAADS and Corgenix labels, as well as
products sold under other manufacturers' labels, referred to as OEM products. An
integral part of our strategy is to work with corporate partners to develop
market opportunities and access important resources. We believe that our
relationships with current and potential partners will enable us to enhance our
menu of diagnostic products and accelerate our ability to penetrate the
worldwide markets for new products.

      We currently use the REAADS and Corgenix trademarks and trade names in the
sale of the products which we manufacture. These products constitute the
majority of our product sales.

      Management of the Company has made a number of estimates and assumptions
 relating to the reporting of assets and liabilities and the disclosure of
 contingent assets and liabilities to prepare these financial statements in
 conformity with accounting principles generally accepted in the United States
 of America. Significant assumptions inherent in the preparation of the
 accompanying financial statements include, but are not limited to, revenue
 recognition and allowances for doubtful accounts, the provision for excess and
 obsolete inventories, and commitments and contingencies. Actual results could
 differ from those estimates.


  2.     EARNINGS (LOSS) PER SHARE

      Basic earnings (loss) per share is computed by dividing net loss
attributable to common stockholders by the weighted average number of common
shares outstanding. Diluted earnings (loss) per share is computed by dividing
net loss attributable to common stockholders by the weighted average number of
common shares outstanding, increased for potentially dilutive common shares
outstanding during the period. The dilutive effect of stock options and their
equivalents is calculated using the treasury stock method. No stock options were
granted in the most recent quarter or six months ended December 31, 2005 or
2004. Options and warrants to purchase common stock totaling 33,221,103 shares
for the quarter and six months ended December 31, 2005, and totaling 1,370,920
shares for the quarter and six months ended December 31, 2004 are not included
in the calculation of weighted average common shares-diluted below as their
effect is anti-dilutive. Redeemable common stock is included in the common
shares outstanding for purposes of calculating net loss per share.

The components of basic and diluted loss per share are as follows:
                               3 months   3 months     6 months     6 months
                                ended       ended        ended       ended
                            December 31, December 31, December 31,  December 31,
                                 2005        2004         2005         2004
                            ---------------------------------------------------


Net loss  available  to
common shareholders        $ (260,527)    (123,677)     (384,635)   (335,515)
                           ====================================================

Common and common equivalent shares outstanding:
  Historical   common   shares
   outstanding    for    basic
   income  (loss) per share at
   beginning of  period     8,587,390     5,324,818     8,172,435    5,321,319

  Weighted    average   common
   shares issued during
   the period                 436,105       12,240        528,839        9,619
                               ------------------------------------------------

  Weighted    average   common
   shares-basic and diluted  9,023,495     5,337,058     8,701,274    5,330,938
Net loss per  share-basic
   and diluted               $  (0.03)        (0.02)         (0.05)       (0.06)
                             ==========    =========     ==========   ==========

3.     INCOME TAXES

    A valuation allowance was provided for deferred tax assets, as the Company
is unable to conclude under relevant accounting standards that it is more likely
than not that deferred tax assets will be realizable.

4.    SEGMENT INFORMATION

   The Company has two segments of business: North American and international
operations. North American operations transacts all sales in North America (US,
Canada and Mexico). International operations transacts all other sales. The
following table sets forth selected financial data for these segments for the
three-and six-month periods ended December 31, 2005 and 2004.


           Three Months Ended December 31,        Six Months Ended December 31,
                                                          31,
           Domestic    Intnl.   Total         Domestic     Intnl.    Total

Net
sales
2005     $1,150,686   430,197 1,580,883      2,396,204    819,632  3,215,836
2004     $  904,689   371,882 1,276,571      1,878,964    700,678  2,579,642
         ----------  --------  -------       ---------   --------- --------
         ==========  ========  =======       =========   =========  ========
Net income
(loss)
2005     $(426,117)   165,590 (260,527)     (713,874)     329,239  (384,635)
2004     ==========  ========  =======       =======      ========= ========
         $(208,712)   106,674 (102,038)     (464,903)     172,666  (292,237)
         ==========  ========  =======       =======      ========= ========

Depreciation
and
amortization
2005     $  23,443       1,037   24,480        70,397      1,472   71,869
2004     $  47,396         569   47,965        92,900      1,133   94,033
         ==========    ========  =======       =======  ========= ========
Interest
expense, net
2005     $(343,453)       (993) (344,446)    (679,443)    (2,873)  (682,316)
2004     $ (84,930)     (1,011)  (85,941)    (188,119)    (2,025)  (190,144
         ----------    --------  -------      -------    --------- --------
         ==========    ========  =======      =======    ========= ========
Segment
assets
2005     $8,012,924     535,743 8,548,667    8,012,924    535,743  8,548,667
June 30,
2005     $4,553,888     438,606 4,992,494    4,553,888    438,606  4,992,494
         ==========    ========  =======      =======    =========  ========


5.    REDEEMABLE COMMON STOCK

      On July 1, 2002, as part of the Medical & Biological Laboratories Co.,
  Ltd. (MBL) Agreement, MBL purchased shares of the Company's common stock for
  $500,000, which, at the time, MBL was permitted to put to the Company for
  repurchase at the same price if a previously existing distribution agreement
  with RhiGene, Inc. were terminated. For no additional consideration, MBL was
  also issued warrants to purchase an additional 880,282 shares of Common Stock
  at a price of $.568 per share, which is equal to an aggregate amount of
  $500,000. These warrants originally were set to expire on July 3, 2007 and may
  be exercised in whole or in part at any time prior to their expiration. The
  estimated fair value of the warrant upon issuance was calculated as $401,809
  using the Black-Scholes option-pricing model with the following assumptions:
  no expected dividend yield, 143% volatility, risk free interest rate of 4.2%
  and an expected life of five years. The gross proceeds of $500,000 were
  allocated $277,221 to redeemable common stock and $222,779 to the related
  warrants based on the relative fair values of the respective instruments to
  the fair value of the aggregate transaction. Issuance costs and the discount
  attributed to the redeemable common stock upon issuance were accreted over the
  33-month period to the first date whereupon the put option may be exercised,
  which was the expiration date of the distribution agreement between the
  Company and RhiGene, Inc. (March 31, 2005). Furthermore, pursuant to the
  agreement with MBL, as long as MBL holds at least 50% of the common stock
  purchased under the MBL agreement, MBL must give its written consent with
  respect to the payment of any dividend, the repurchase of any of the Company's
  equity securities, the liquidation or dissolution of the Company or the
  amendment of any provision of the Company's Articles of Incorporation or
  Bylaws which would adversely affect the rights of MBL under the stock purchase
  transaction documents. MBL was granted standard anti-dilution rights with
  respect to stock issuances not registered under the Securities Act and
  received standard piggyback registration rights along with certain demand
  registration rights. MBL did not elect to register its redeemable shares in
  the SB-2 registration statement filed by the Company on June 25, 2005 and
  declared effective on August 2, 2005.

      On March 31, 2005 our distribution agreement with RhiGene expired, and the
Company signed a new distribution and OEM Supply Agreement with MBL
International, Inc. ("MBLI"), a wholly owned subsidiary of MBL, which grants the
Company non-exclusive rights to distribute MBL's complete diagnostic line of
autoimmune testing products in the United States and exclusive distribution
rights to the OEM Label products worldwide excluding the United States, Japan,
Korea and Taiwan. In addition, on August 1, 2005 the Company and MBL executed an
Amendment to the Common Stock Purchase Agreement and Common Stock Purchase
Warrant wherein one-half or 440,141of the original redeemable shares are to be
exchanged over time for a three-year promissory note payable with interest at
prime (6.75% as of September 30, 2005) plus two percent with payments having
commenced in September, 2005. The shares exchanged for the promissory note will
be returned to the Company quarterly on a pro rata basis as payments are made on
the promissory note. The remaining 440,141 shares must be redeemable by the
Company at $0.568 per share as of August 1, 2008 for any shares still owned at
that time by MBL and only to the extent that MBL has not realized at least
$250,000 in gross proceeds upon the sales of its redeemable shares in the open
market for the time period August 1, 2005 through August 30, 2008. Finally, the
warrants originally issued to MBL to purchase 880,282 shares have been extended
to August 31, 2008 and re-priced from $0.568 per share to $0.40 per share.

    6.  STOCK PLANS


      The Company accounts for its stock plans in accordance with the provisions
of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued
to Employees, SFAS No.148, Accounting for Stock-Based Compensation-Transition
and Disclosure, and related interpretations. As such, compensation expense is
recorded on the date of grant only if the current market price of the underlying
stock exceeds the exercise price. SFAS No. 123, Accounting for Stock-Based
Compensation, permits entities to recognize as expense over the vesting period
the fair value of all stock-based awards on the date of grant. Alternatively,
SFAS No. 123 also allows entities to continue to apply the provisions of APB
Opinion No. 25 and provide pro forma net loss disclosures for employee stock
option grants as if the fair-value-based method defined in SFAS No. 123 had been
applied. The Company has elected to continue to apply the provisions of APB
Opinion No. 25 and provide the pro forma disclosures required by SFAS No. 123.

      Had the Company determined compensation cost based on the fair value at
the date of grant for its stock options under SFAS No. 123, the Company's net
loss would have been increased to the pro forma amounts indicated as follows:

                                 Three     Three      Six        Six
                                Months     Months     Months     Months
                                 Ended     Ended      Ended      Ended
                                -----------------------------------------
                                December  December   December   December
                                   31,        31,       31,         31,
                                -----------------------------------------
                                 2005       2004       2005        2004
                                -----------------------------------------
                                -----------------------------------------

  Net  loss   available   to
    common  stockholders  as
    reported                    $(260,527) $(123,677) $(384,635)  $(335,515)
  Deduct  total  stock-based
    employee    compensation
    expense       determined
    under fair-value  method
    for all  awards,  net of tax  (16,977)  (10,679)   (33,954)   (21,358)
                                  --------  ---------  ---------  ---------
  Pro forma net loss
    available to common $
    stockholders                $(277,504) (134,356)   (418,589)  (356,873)
                                  ========= ========   =========  =========
  Net loss per share basic
    and diluted as reported     $  (0.03)  $  (0.02)    $ (0.04)  $  (0.06)
                                  =======   =========   ========  =========
  Net loss per share, basic
     and diluted  pro forma     $   (0.03) $  (0.03)    $ (0.05)  $   (0.07)
                                  =======   =========   ========  ==========

      As of December 31, 2005, there were also 31,836,226 outstanding warrants
issued to institutional investors, consultants and employees outstanding and
exercisable ranging in prices from $.23 to $1.25 per share with a weighted
average exercise price of $.38 per share. Fair value was determined using the
Black Scholes option - pricing model with the following assumptions: no expected
dividends, volatility of 111.5% in fiscal 2005, risk-free interest rate of 4.39
% in fiscal 2006 and expected lives of five to seven years.

   7.  RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

      FAS 123R Disclosure. In December 2004, the FASB issued SFAS No. 123(R),
Share-Based Payment, which is a revision of SFAS No. 123, Accounting for
Stock-Based Compensation. SFAS No. 123(R) will be effective for the Company
beginning January 1, 2006, and supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. SFAS
No. 123(R) requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the income statement based on their
fair values. Pro-forma disclosure is no longer an alternative. The Company does
not expect the adoption of FAS 123(R) will have a material impact on the
Company's financial statements.

      FAS 154 Disclosure. In June 2005, the FASB issued SFAS No. 154, Accounting
Changes and Error Corrections, a replacement of APB Opinion No. 20 and SFAS No.
3. The statement applies to all voluntary changes in accounting principles, and
changes the requirements for accounting for and reporting of a change in
accounting principle. The Company does not believe the adoption of SFAS No. 154
will have a material impact on the Company's financial statements.

8.    NOTES PAYABLE

      Notes payable consist of the following at December 31, 2005 and June 30,
2005:
                                               December 31, 2005  June 30, 2005
                                               -----------------  -------------

    Secured, amortizing convertible term note
    payable to institutional investors,
    net of discount of $842,856, with interest at the
    greater of 12% or prime plus 3%
    (12% as of  December 31, 2005),
    interest only from June 1, 2005 through
    October 1, 2005 and then due in monthly
    installments of $55,667 plus interest
    through May 19, 2008, collateralized by
    commercial security agreements and a
    partial guaranty by an officer of the
    company. See discussion of terms below.       $  714,310     451,892

    Secured, amortizing convertible term
    note payable to institutional investors,
    net of discount of $1,492,456, with interest
    at the greater of 12% or prime plus 3%
    (12% as of  December 31, 2005),
    interest only from December 28, 2005
    through June1, 2006 and then due in
    monthly installments of $50,000 plus
    interest through December 28, 2008,
    collateralized by commercial security
    agreements. See discussion of terms
    below.                                           7,544          --

    Secured, non-amortizing convertible
    term note payable to institutional investors,
    with interest at the greater of 12% or prime
    plus 3% (12% as of June 30, 2005), interest
    only payments commencing June 1, 2005
    until May 19, 2008, collaterialized by
    commercial security agreements. See
    discussion of terms below.                    500,000          500,000

    Secured, restricted, non-amortizing
    convertible term note payable to institutional
    investors, with interest at prime (6% at June 30,
    2005), interest only payments commencing June 1,
    2005 until the earlier of May 19, 2008 or
    the date the proceeds to the company are no
    longer restricted, collateralized by
    commercial security agreements. See discussion
    of terms below.                              250,000           250,000

    Note payable, unsecured, to redeemable
    common stockholders, with interest at prime
    plus 2.0% (8.75% at December 31, 2005) due
    in monthly installments with principal
    payments ranging from $5,000 to $10,000 plus
    interest through August 2008.                230,000              --
                                               -----------        ------------
                                               1,701,854           1,201,892

       Current portion,  net of current
          portion of discount                   (507,414)           (221,176)
                                               -----------         ------------
                 Notes payable, excluding
                 current portion              $ 1,194,440             980,716
                                              ===========          ============

The Company completed a second convertible debt financing on December 28,
2005. The financing was a private placement financing with certain institutional
and other accredited investors that had previously invested in the Company,
including Truk International Fund, LP, Truk Opportunity Fund, LLC and CAMOFI
Master LDC (f/k/a DCOFI Master LDC), representing net proceeds to the Company of
$1,363,635. This financing was made pursuant to the exercise of an additional
investment right by such institutional investors that was granted to them
pursuant to a financing on substantially similar terms completed on May 19,
2005.

      This private placement includes $1,500,000 in aggregate principal amount
of Secured Convertible Term Notes due 2008. Warrants to acquire approximately
3,800,000 shares of the Company's common stock, at $0.23 per share, were also
issued to the investors (the AIR Warrants).

      The interest rate on the Secured Convertible Term Notes is the greater of
(i) prime rate plus 3% or (ii) 12%, except for the portion of the note proceeds
that is held in the restricted cash account, which amount accrues interest at
the prime rate. However, (i) if the Company has registered the shares of common
stock underlying the Secured Convertible Term Notes and the AIR Warrants, and
that registration is declared effective, and (ii) the market price of the common
stock for the five consecutive trading days preceding the last business day of
each month exceeds the conversion price (as adjusted) by 25%, then the interest
rate for the next calendar month is reduced by 25 basis points for each
incremental 25% increase in the market price above the fixed conversion price.

      Amortizing payments of the principal amount begin on June 1, 2006 and such
payments are due on the first day of each month thereafter until the maturity
date in December 2008, at which time any outstanding principal shall be due and
payable. Interest payments begin January 1, 2006, and such interest payments are
due on the first day of each subsequent month until the principal amount is paid
in full.

      The Secured Convertible Term Notes may be prepaid, but any prepayment must
be 125% of the portion of the principal amount to be prepaid, together with
accrued but unpaid interest thereon and any other sums due. The holders of the
Secured Convertible Term Notes may accelerate all sums of principal, interest
and other fees then remaining unpaid upon the occurrence of an event of default
(as defined in the Secured Convertible Term Notes) beyond any applicable grace
period. In the event of such acceleration, the amount due and owing the holder
shall be 125% of the outstanding principal amount (plus accrued and unpaid
interest and fees, if any). As part of the financing terms, a blanket lien filed
in connection with the May 19, 2005 financing covering all of the Company's
assets extends to this financing.

      The number of shares of common stock to be issued upon conversion of a
Secured Convertible Term Note is determined by dividing that portion of the
principal amount, interest and fees to be converted by the then applicable
conversion price, which is initially set at $0.30. The conversion price may be
adjusted to account for certain events, such as stock splits, combinations,
dividends and share issuances below the then current conversion price.

      The conversion right as contained in the Secured Convertible Term Notes
provide that a holder will not convert an amount of a Note that would be
convertible into shares of common stock to the extent that the number of shares
held by the holder, when added to the number of shares of common stock
beneficially owned by such holder or issuable if the holder exercised one or
more of its AIR Warrants immediately prior to conversion, would exceed 4.99% of
the Company's issued and outstanding common stock.

      The Company also issued AIR Warrants to acquire approximately 3,800,000
shares of the Company's common stock. The AIR Warrants are exercisable for seven
years from the date of issuance at an exercise price of $0.23 per share. The
exercise price is also subject to adjustment upon the occurrence of certain
specified events, including issuance of additional shares of common stock or
subdivision or combining of shares of common stock.

      The transaction also included a Registration Rights Agreement in which the
Company has agreed to file a registration statement on Form SB-2 covering the
shares of common stock issuable upon the exercise of the AIR Warrants and the
conversion of the Secured Convertible Term Notes. If the registration statement
is declared effective or is otherwise ineffective or incomplete on the time
schedule cited in the Registration Rights Agreement, the Company shall pay the
holders of the Secured Convertible Term Notes or AIR Warrants liquidated damages
in the amount of 1.5% on the original principal amount of Secured Convertible
Term Notes for each 30-day period that elapses until the registration statement
is declared effective.
                                     Item 2.




                          CORGENIX MEDICAL CORPORATION
                    Management's Discussion and Analysis of
                 Financial Condition and Results of Operations



       The following discussion should be read in conjunction with the
consolidated financial statements and accompanying notes included elsewhere
herein.


      General


      Since the Company's inception, we have been primarily involved in the
research, development, manufacturing and marketing/distribution of diagnostic
tests for sale to clinical laboratories. We currently market 51 products
covering autoimmune disorders, cardiovascular diseases, and liver disease. Our
products are sold in the United States, the UK and other countries through our
marketing and sales organization that include contract sales representatives,
internationally through an extensive distributor network, and to several
significant OEM partners.

      We manufacture products for inventory based upon expected sales demand,
shipping products to customers, usually within 24 hours of receipt of orders if
in stock. Accordingly, we do not usually operate with a customer order backlog.

      Except for the fiscal year ending June 30, 1997, we have experienced
annual revenue growth since our inception, primarily from sales of products and
contract revenues from strategic partners. Contract revenues consist of service
fees from research and development agreements with strategic partners.

      Beginning in fiscal year 1996, we began adding third-party OEM licensed
products to our diagnostic product line. Currently we sell 128 products licensed
from or manufactured by third party manufacturers. We expect to expand our
relationships with other companies in the future to gain access to additional
products.

      Although we have experienced growth in revenues every year since 1990,
except for 1997, there can be no assurance that, in the future, we will sustain
revenue growth, current revenue levels, or achieve or maintain profitability.
Our results of operations may fluctuate significantly from period-to-period as
the result of several factors, including: (i) whether and when new products are
successfully developed and introduced, (ii) market acceptance of current or new
products, (iii) seasonal customer demand, (iv) whether and when we receive
research and development payments from strategic partners, (v) changes in
reimbursement policies for the products that we sell, (vi) competitive pressures
on average selling prices for the products that we sell, and (vii) changes in
the mix of products that we sell.

      Recently Issued Accounting Pronouncements

      FAS 123R Disclosure. In December 2004, the FASB issued SFAS No. 123(R),
Share-Based Payment, which is a revision of SFAS No. 123, Accounting for
Stock-Based Compensation. SFAS No. 123(R) will be effective for the Company
beginning January 1, 2006, and supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. SFAS
No. 123(R) requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the income statement based on their
fair values. Pro-forma disclosure is no longer an alternative. The Company does
not expect the adoption of FAS 123(R) will have a material impact on the
Company's financial statements.

      FAS 154 Disclosure. In June 2005, the FASB issued SFAS No. 154, Accounting
Changes and Error Corrections, a replacement of APB Opinion No. 20 and SFAS No.
3. The statement applies to all voluntary changes in accounting principles, and
changes the requirements for accounting for and reporting of a change in
accounting principle. The Company does not believe that the adoption of SFAS No.
154 will have a material impact on the Company's financial statements.


      Critical Accounting Policies

      The Company's consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United States ("GAAP") and
our significant accounting policies are summarized above. The preparation of
financial statements in conformity with GAAP requires management to make
estimates and assumptions that affect reported amounts of assets, liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements and reported amounts of revenues and expenses during the reporting
period. Actual results could differ significantly from those estimates.

      The Company maintains an allowance for doubtful accounts based on its
historical experience and provides for any specific collection issues that are
identified. Such allowances have historically been adequate to provide for our
doubtful accounts but involve a significant degree of management judgment and
estimation. Worse than expected future economic conditions, unknown customer
credit problems and other factors may require additional allowances for doubtful
accounts to be provided for in future periods.

      Equipment and software are recorded at cost. Equipment under capital
leases is recorded initially at the present value of the minimum lease payments.
Depreciation and amortization is calculated primarily using the straight-line
method over the estimated useful lives of the respective assets that range from
3 to 7 years.

      The internal and external costs of developing and enhancing software costs
related to website development, other than initial design and other costs
incurred during the preliminary project stage, are capitalized until the
software has been completed. Such capitalized amounts began to be amortized
commencing when the website was placed in service on a straight-line basis over
a three-year period.

      When assets are sold, retired or otherwise disposed of, the cost and
related accumulated depreciation are eliminated from the accounts and a gain or
loss is recognized.

      Repair and maintenance costs are expensed as incurred.

      We evaluate the realizability of our long-lived assets, including property
and equipment, whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable.

      Revenue from sale of products is recognized upon shipment of products.

      Revenue from research and development contracts represents amounts earned
pursuant to agreements to perform research and development activities for third
parties and is recognized as earned under the respective agreement. Because
research and development services are provided evenly over the contract period,
revenue is recognized ratably over the contract period. Research and development
agreements in effect in 2005 and 2004 provided for fees to the Company based on
time and materials in exchange for performing specified research and development
functions. Research and development and advertising costs are expensed when
incurred. Inventories are recorded at the lower of cost or market, using the
first-in, first-out method.

      Results of Operations


       Three Months Ended December 31, 2005 compared to 2004

      Net sales. Net sales for the quarter ended December 31, 2005 were
approximately $1,581,000, a 23.8% increase from approximately $1,277,000 for the
quarter ended December 31, 2004. North American sales increased 27.2%, while
sales to international distributors increased 15.7% from year to year for the
second quarter, due to an overall increase in demand for and increased
acceptance of the Company's diagnostic kits. With respect to the Company's major
product lines, Phospholipids kit sales increased 22.0% for the fiscal quarter,
Coagulation kit sales increased 20.0 %, HA kit sales increased 21.4%, primarily
due to the timing of orders, and Autoimmune kit sales increased 34.9%.
Additionally, OEM sales increased 9.2%. Sales of products manufactured for us by
other companies while still relatively small, are expected to continue to
increase during fiscal 2006.

      Cost of sales. Cost of sales, as a percentage of sales, increased slightly
to 36.5% in the quarter ended December 31, 2005 from 35.3% in the second quarter
of 2004 primarily due to product mix contribution from lower gross margin
products.

      Selling and marketing. For the quarter ended December 31, 2005, selling
and marketing expenses decreased less than 1% to approximately $366,000 from
approximately $369,000 in the second quarter of 2004. The slight decrease was
due to decreases in CE Marking, license fees, and business promotional expenses
offset by increases in commissions expense, labor related, trade show and
royalties expense.

      Research and development. Research and development expenses increased
10.3% to approximately $153,000 in the quarter ended December 31, 2005 from
approximately $139,000 for the quarter ended December 31, 2004 as a result of
increased activity related to certain larger-market new product opportunities .
The majority of this increase involved increases in convention and seminar
participations and related fees, legal fees, outside services, travel and
laboratory supplies.

      General and administrative. General and administrative expenses increased
approximately $66,000 or 19.8% to approximately $400,000 in the quarter ended
December 31, 2005 from approximately $334,000 for the quarter ended December 31,
2004, primarily due to increases in consulting fees, labor-related expenses,
outside services (primarily investor relations and proxy-related), and patent
renewal fees.

      Interest expense. Interest expense increased 300.8% to approximately
$344,000 for the quarter ended December 31, 2005 from approximately $86,000 in
2004 due primarily to the amortization of deferred financing costs and discount
on the notes payable to the institutional investors in the recently completed
convertible debt financings.

      Six Months Ended December 31, 2005 and 2004

      Net sales Net sales for the six months ended December 31, 2005 were
approximately $3,216,000, a 24.7% increase from approximately $2,580,000 for the
six months ended December 31, 2004. Domestic sales increased 27.5% while sales
to international distributors increased 17.0% from year to year due to an
overall increase in demand for and increased acceptance of the Company's
diagnostic kits. With respect to the Company's major product lines,
Phospholipids kit sales increased 17.7% for the current six month period,
Coagulation kit sales increased 14.0 %, HA kit sales increased 37.5%, and
Autoimmune kit sales decreased 3.3%. Additionally, OEM sales increased 26.8%.
Sales of products manufactured for us by other companies while still relatively
small, are expected to continue to increase during fiscal 2006.

      Cost of sales. Cost of sales, as a percentage of sales, decreased to 36.1%
in the six months ended December 31, 2005 from 39.1% in 2004 primarily due to
product mix contribution from higher gross margin products.

      Selling and marketing. Selling and marketing expenses increased less than
1% to approximately $746,000 in the six months ended December 31, 2005 from
approximately $744,000 in 2004. The majority of this increase involved increases
in commissions expense, labor related, trade show and royalties expense, offset
by decreases in CE Marking, license fees, and business promotional expenses.

      Research and development. Research and development expenses decreased 4.6%
to approximately $282,000 in the six months ended December 31, 2005 from
approximately $295,000 for the six months ended December 31, 2004. The majority
of this decrease involved reductions in consulting, and labor-related expenses
essentially offset by increases in convention and seminars, legal fees, outside
services, travel and laboratory supplies.

      General and administrative. General and administrative expenses increased
approximately $97,000 or 15.3% to approximately $731,000 in the six months ended
December 31, 2005 from approximately $634,000 for the six months ended December
31, 2004, primarily due to increases in consulting fees, labor-related expenses,
outside services (primarily investor relations and proxy-related), and patent
renewal fees.

      Interest expense. Interest expense increased 258.8% to approximately
$682,000 in the six months ended December 31, 2005 from approximately $190,000
for the six months ended December 31, 2004 due primarily to the amortization of
deferred financing costs and discount on the notes payable to the institutional
investors in the recently completed convertible debt financings.
      .
      Liquidity and Capital Resources

      Cash used in operating activities was $482,309 for the first six months
of the current fiscal year compared to cash provided in operating activities of
$91,943 during the prior year's first six months. The cash used in operations
resulted primarily from increases in prepaid expenses (principally deferred
financing costs) and other assets plus increases in inventories and accounts
receivable and decreases in accounts payable and accrued liabilities. The
Company believes that uncollectible accounts receivable will not have a
significant effect on future liquidity, as a significant portion of its accounts
receivable are due from financially sound enterprises.

      Net cash used by investing activities, the purchase of equipment, was
$28,867 in the initial six months compared to $12,635 for the prior year's same
period. The increase was mainly attributable to increased spending on computers,
refrigeration equipment and manufacturing equipment.

      Net cash provided by financing activities amounted to $1,341,703 during
the recent initial six months compared to cash used by financing activities of
$131,043 in the prior fiscal year. This decrease in cash used versus the
comparable prior year was primarily due to the financings discussed above.

      Historically, we have financed our operations primarily through long-term
debt and sales of common, redeemable common and preferred stock. We have also
financed operations through sales of diagnostic products and agreements with
strategic partners. Accounts receivable increased 21.5% to $1,078,262 from
$887,645 in 2004 primarily as a result of sales increases during the period.

      Our future capital requirements will depend on a number of factors,
including the ability to complete new equity or debt financing, the possible
redemption of common stock, our profitability or lack thereof, the rate at which
we grow our business and our investment in proprietary research activities, the
ability of our current and future strategic partners to fund outside research
and development activities, our success in increasing sales of both existing and
new products and collaborations, expenses associated with unforeseen litigation,
regulatory changes, competition, technological developments, general economic
conditions and potential future merger and acquisition activity. Our principal
sources of liquidity have been cash raised from the private sale of secured
convertible term notes and the sale of redeemable common, common and preferred
stock, the Bridge Note from Genesis, and long-term bank debt financing. We
believe that our current availability of cash, working capital, proceeds from
the issuance of preferred or common stock and debt financing and expected cash
flows from operations, especially considering the increasing sales volume the
Company is experiencing in Fiscal 2006, will be adequate to meet our ongoing
needs for at least the next twelve months.













                                       Item 3.

                               Controls and Procedures

         Evaluation of disclosure controls and procedures. The Company, under
the supervision and with the participation of the Company's management,
including its Chief Executive Officer and Chief Financial Officer, carried out
an evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in Rules 240.13a-14(c) and
15d-14(c) under the Securities Exchange Act of 1934 (the "Exchange Act") as of
the end of the period covered by this quarterly report (the "Evaluation Date").
Based upon this evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that, as of the Evaluation Date, the Company's disclosure
controls and procedures were effective for the purposes of recording,
processing, summarizing and timely reporting information required to be
disclosed by the Company in the reports that it files under the Securities
Exchange Act of 1934 and that such information is accumulated and communicated
to the Company's management in order to allow timely decisions regarding
required disclosure.

          Changes in internal controls. There have been no significant changes
in the Company's internal controls or in other factors that could significantly
affect the Company's disclosure controls and procedures subsequent to the
Evaluation Date, nor were there any significant deficiencies or material
weaknesses in the Company's internal controls.


      Forward-Looking Statements and Risk Factors

      This 10-QSB includes statements that are not purely historical and are
"forward-looking statements" within the meaning of Section 21E of the Securities
Act of 1934, as amended, including statements regarding our expectations,
beliefs, intentions or strategies regarding the future. All statements other
than historical fact contained in this 10-QSB, including, without limitation,
statements regarding future product developments, acquisition strategies,
strategic partnership expectations, technological developments, the availability
of necessary components, research and development programs and distribution
plans, are forward-looking statements. All forward-looking statements included
in this 10-QSB are based on information available to us on the date hereof, and
we assume no obligation to update such forward-looking statements. Although we
believe that the assumptions and expectations reflected in such forward-looking
statements are reasonable, we can give no assurance that such expectations will
prove to have been correct or that we will take any actions that may presently
be planned.

      Certain factors that could cause actual results to differ materially from
those expected include the following:

      We continue to incur losses and the Company requires additional financing.

      We have incurred operating losses and negative cash flow from operations
for most of our history. Losses incurred since our inception have aggregated
$5,885,779 and there can be no assurance that we will be able to generate
positive cash flows to fund our operations in the future or to pursue our
strategic objectives. Assuming no significant changes from our budget, we
believe that we will have sufficient cash to satisfy our needs for at least the
next twelve months. If we are not able to operate profitably and generate
positive cash flows, we will undoubtedly need to raise additional capital, most
likely via the sale of equity securities, to fund our operations. If we do in
fact need additional financing to meet our requirements, there can be no
assurance that we will be able to obtain such financing on terms satisfactory to
us, if at all. Alternatively, any additional equity financing may be dilutive to
existing stockholders, and debt financing, if available, may include restrictive
covenants. If adequate funds are not available, we might be required to limit
our research and development activities or our selling, marketing and
administrative activities any of which could have a material adverse effect on
the future of the business.

      We depend upon collaborative relationships and third parties for product
      development and commercialization.

      We have historically entered into research and development agreements with
collaborative partners, from which we derived revenues in past years. Pursuant
to these agreements, our collaborative partners have specific responsibilities
for the costs of development, promotion, regulatory approval and/or sale of our
products. We will continue to rely on future collaborative partners for the
development of products and technologies. There can be no assurance that we will
be able to negotiate such collaborative arrangements on acceptable terms, if at
all, or that current or future collaborative arrangements will be successful. To
the extent that we are not able to establish such arrangements, we could be
forced to undertake such activities at our own expense. The amount and timing of
resources that any of these partners devotes to these activities will generally
be based on progress by us in our product development efforts. Collaborative
arrangements may be terminated by the partner upon prior notice without cause
and there can be no assurance that any of these partners will perform its
contractual obligations or that it will not terminate its agreement. With
respect to any products manufactured by third parties, there can be no assurance
that any third-party manufacturer will perform acceptably or that failures by
third parties will not delay clinical trials or the submission of products for
regulatory approval or impair our ability to deliver products on a timely basis.

      There can be no assurance of successful or timely development of
additional products.

      Our business strategy includes the development of additional diagnostic
products for the diagnostic business. Our success in developing new products
will depend on our ability to achieve scientific and technological advances and
to translate these advances into commercially competitive products on a timely
basis. Development of new products requires significant research, development
and testing efforts. We have limited resources to devote to the development of
products and, consequently, a delay in the development of one product or the use
of resources for product development efforts that prove unsuccessful may delay
or jeopardize the development of other products. Any delay in the development,
introduction and marketing of future products could result in such products
being marketed at a time when their cost and performance characteristics would
not enable them to compete effectively in their respective markets. If we are
unable, for technological or other reasons, to complete the development and
introduction of any new product or if any new product is not approved or cleared
for marketing or does not achieve a significant level of market acceptance, our
ability to remain competitive in our product niches would be impaired.

      Competition in the human medical diagnostics industry is, and is expected
      to remain, significant.

      Our competitors range from development stage diagnostics companies to
major domestic and international pharmaceutical companies. Many of these
companies have financial, technical, marketing, sales, manufacturing,
distribution and other resources significantly greater than ours. In addition,
many of these companies have name recognition, established positions in the
market and long standing relationships with customers and distributors.
Moreover, the diagnostics industry has recently experienced a period of
consolidation, during which many of the large domestic and international
pharmaceutical companies have been acquiring mid-sized diagnostics companies,
further increasing the concentration of resources. There can be no assurance
that technologies will not be introduced that could be directly competitive with
or superior to our technologies.

      Our products and activities are subject to regulation by various
      governments and government agencies.

      The testing, manufacture and sale of our products is subject to regulation
by numerous governmental authorities, principally the United States Food and
Drug Administration, referred to as the FDA, and certain foreign regulatory
agencies. Pursuant to the Federal Food, Drug, and Cosmetic Act, and the
regulations promulgated there under, the FDA regulates the preclinical and
clinical testing, manufacture, labeling, distribution and promotion of medical
devices. We are limited in our ability to commence marketing or commercial sales
in the United States of new products under development until we receive
clearance from the FDA. The testing for, preparation of and subsequent FDA
regulatory review of required filings can be a lengthy, expensive and uncertain
process. Noncompliance with applicable requirements can result in, among other
consequences, fines, injunctions, civil penalties, recall or seizure of
products, repair, replacement or refund of the cost of products, total or
partial suspension of production, failure of the government to grant pre-market
clearance or pre-market approval for devices, withdrawal of marketing clearances
or approvals, and criminal prosecution.

      There can be no assurance that we will be able to obtain necessary
regulatory approvals or clearances for our products on a timely basis, if at
all, and delays in receipt of or failure to receive such approvals or
clearances, the loss of previously received approvals or clearances, limitations
on intended use imposed as a condition of such approvals or clearances or
failure to comply with existing or future regulatory requirements could
negatively impact our sales and thus have a material adverse effect on our
business.

      As a manufacturer of medical devices for marketing in the United States,
we are required to adhere to applicable regulations setting forth detailed good
manufacturing practice requirements, which include testing, control and
documentation requirements. We must also comply with Medical Device Report (MDR)
requirements, which require that a manufacturer reports to the FDA any incident
in which its product may have caused or contributed to a death or serious
injury, or in which its product malfunctioned and, if the malfunction were to
recur, it would be likely to cause or contribute to a death or serious injury.
We are also subject to routine inspection by the FDA for compliance with Quality
System Regulations (QSR) requirements, MDR requirements and other applicable
regulations. Labeling and promotional activities are subject to scrutiny by the
FDA and, in certain circumstances, by the Federal Trade Commission. We may incur
significant costs to comply with laws and regulations in the future, which would
decrease our net income or increase our net loss and thus have a potentially
material adverse effect upon our business, financial conditions and results of
operations.

      Distribution of diagnostic products outside the United States is subject
to extensive foreign government regulation. These regulations, including the
requirements for approvals or clearance to market, the time required for
regulatory review and the sanctions imposed for violations, vary from country to
country. We may be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals. In addition, the export of certain of
our products that have not yet been cleared for domestic commercial distribution
may be subject to FDA export restrictions. Failure to obtain necessary
regulatory approval or the failure to comply with regulatory requirements could
reduce our product sales and thus have a potentially material adverse effect on
our business, financial condition and results of operations.

      We depend upon distribution partners for sales of diagnostic products in
international markets.

      We have entered into distribution agreements with collaborative partners
in which we have granted distribution rights for certain of our products to
these partners within specific international geographic areas. Pursuant to these
agreements, our collaborative partners have certain responsibilities for market
development, promotion, and sales of the products. If any of these partners
fails to perform its contractual obligations or terminates its agreement, this
could have a reduce our sales and cash flow and thus have a potentially material
adverse effect on our business, financial condition and results of operations.

      Third party reimbursement for purchases of our diagnostic products is
      uncertain.

      In the United States, health care providers that purchase diagnostic
products, such as hospitals and physicians, generally rely on third party
payers, principally private health insurance plans, federal Medicare and state
Medicaid, to reimburse all or part of the cost of the purchase. Third party
payers are increasingly scrutinizing and challenging the prices charged for
medical products and services and they can affect the pricing or the relative
attractiveness of the product. Decreases in reimbursement amounts for tests
performed using our diagnostic products, failure by physicians and other users
to obtain reimbursement from third party payers, or changes in government and
private third party payers' policies regarding reimbursement of tests utilizing
diagnostic products, may affect our ability to sell our diagnostic products
profitably. Market acceptance of our products in international markets is also
dependent, in part, upon the availability of reimbursement within prevailing
health care payment systems.

      Our success depends, in part, on our ability to obtain patents and license
      patent rights, to maintain trade secret protection and to operate without
      infringing on the proprietary rights of others.

      There can be no assurance that our issued patent will afford meaningful
protection against a competitor, or that patents issued or assigned to us will
not be infringed upon or designed around by others, or that others will not
obtain patents that we would need to license or design around. We could incur
substantial costs in defending the Company or our licensees in litigation
brought by others. The potential for reduced sales and increased legal expenses
would have a negative impact on our cash flow and thus our overall business
could be adversely affected.

      We may not be able to successfully implement our plans to acquire other
      companies or technologies.

      Our growth strategy may include the acquisition of complementary
companies, products or technologies. There is no assurance that we will be able
to identify appropriate companies or technologies to be acquired, to negotiate
satisfactory terms for such an acquisition, or to obtain sufficient capital to
make such acquisitions. Moreover, because of limited cash resources, we will be
unable to acquire any significant companies or technologies for cash and our
ability to effect acquisitions in exchange for our capital stock may depend upon
the market prices for our common stock, which could result in significant
dilution to its existing stockholders. If we do complete one or more
acquisitions, a number of risks arise, such as disruption of our existing
business, short-term negative effects on our reported operating results,
diversion of management's attention, unanticipated problems or legal
liabilities, and difficulties in the integration of potentially dissimilar
operations. Any of these factors could materially harm Corgenix's business or
its operating results.

      We depend on suppliers for our products' components.

      The components of our products include chemical and packaging supplies
that are generally available from several suppliers, except certain antibodies,
which we purchase from single suppliers. We mitigate the risk of a loss of
supply by maintaining a sufficient supply of such antibodies to ensure an
uninterrupted supply for at least three months. We have also qualified second
vendors for all critical raw materials and believe that we can substitute a new
supplier with respect to any of these components in a timely manner. If, for
some reason, we lose our main supplier for a given material, there can be no
assurances that we will be able to substitute a new supplier in a timely manner
and failure to do so could impair the manufacturing of certain of our products
and thus have a material adverse effect on our business, financial condition and
results of operations.

      We have only limited manufacturing experience with certain products.

      Although we have manufactured over twelve million diagnostic tests based
on our proprietary applications of ELISA (enzyme linked immuno-absorbent assay)
technology, certain of our diagnostic products in consideration for future
development, incorporate technologies with which we have limited manufacturing
experience. Assuming successful development and receipt of required regulatory
approvals, significant work may be required to scale up production for each new
product prior to such product's commercialization. There can be no assurance
that such work can be completed in a timely manner and that such new products
can be manufactured cost-effectively, to regulatory standards or in sufficient
volume.

      Due to the specialized nature of our business, our success will be highly
      dependent upon our ability to attract and retain qualified scientific and
      executive personnel.

      We believe our success will depend to a significant extent on the efforts
and abilities of Dr. Luis R. Lopez and Douglass T. Simpson, who would be
difficult to replace. There can be no assurance that we will be successful in
attracting and retaining such skilled personnel, who are generally in high
demand by other companies. The loss of, inability to attract, or poor
performance by key scientific and executive personnel may have a material
adverse effect on our business, financial condition and results of operations.

      The testing, manufacturing and marketing of medical diagnostic devices
      entails an inherent risk of product liability claims.

      To date, we have experienced no product liability claims, but any such
claims arising in the future could have a material adverse effect on our
business, financial condition and results of operations. Potential product
liability claims may exceed the amount of our insurance coverage or may be
excluded from coverage under the terms of our policy or limited by other claims
under our umbrella insurance policy. Additionally, there can be no assurance
that our existing insurance can be renewed by us at a cost and level of coverage
comparable to that presently in effect, if at all. In the event that we are held
liable for a claim against which we are not insured or for damages exceeding the
limits of our insurance coverage, such claim could have a material adverse
effect on our cash flow and thus potentially a materially adverse effect on our
business, financial condition and results of operations.

      There has, to date, been no active public market for our common stock, and
      there can be no assurance that an active public market will develop or be
      sustained.

      Although our common stock has been traded on the OTC Bulletin Board(R)
since May 1998, the trading has been sporadic with insignificant volume.

      Moreover, the over-the-counter markets for securities of very small
companies historically have experienced extreme price and volume fluctuations.
These broad market fluctuations and other factors, such as new product
developments, trends in our industry, the investment markets, economic
conditions generally, and quarterly variation in our results of operations, may
adversely affect the market price of our common stock. In addition, our common
stock is subject to rules adopted by the Securities and Exchange Commission
regulating broker-dealer practices in connection with transactions in "penny
stocks." Such rules require the delivery prior to any penny stock transaction of
a disclosure schedule explaining the penny stock market and all associated risks
and impose various sales practice requirements on broker-dealers who sell penny
stocks to persons other than established customers and accredited investors,
which are generally defined as institutions or an investor with a net worth in
excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together
with the spouse. For these types of transactions the broker-dealer must make a
special suitability determination for the purchaser and have received the
purchaser's written consent to the transaction prior to sale. The additional
burdens imposed upon broker-dealers by such requirements may discourage
broker-dealers from effecting transactions in securities subject to the penny
stock rules.

      There are risks associated with fluctuating exchange rates.

   Our financial statements are presented in US dollars. At the end of each
fiscal quarter and the fiscal year, we convert the financial statements of
Corgenix UK, which operates in pounds sterling, into US dollars, and consolidate
them with results from Corgenix, Inc. We may, from time to time, also need to
exchange currency from income generated by Corgenix UK. Foreign exchange rates
are volatile and can change in an unknown and unpredictable fashion. Should the
foreign exchange rates change to levels different than anticipated by us, our
business, financial condition and results of operations may be adversely
affected.



<PAGE>


                          CORGENIX MEDICAL CORPORATION


                                     Part II


                                Other Information





Item 1.    Legal Proceedings


      None.


Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds


       See  disclosure  provided on the Company's  Form 8-K filed  December 29,
2005

Item 3.    Defaults Upon Senior Securities


      None


Item 4.    Submission of Matters to a Vote of Security Holders


      None


Item 5.    Other Information


      None

Item 6.  Exhibits and Reports on Form 8-K.

a. Index to and Description of Exhibits


Exhibit
Number   Description of Exhibit

4.1      Form of Term Note Security Agreement dated May 19, 2005, filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.

4.2      Form of Common Stock Purchase Warrant dated May 19, 2005, filed with
         the Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.

4.3      Amended and Restated Certificate of Designation of
         Preferences, Rights and Limitations of Series A
         Convertible Preferred Stock for Corgenix Medical
         Corporation.
10.1*    Preferred Stock Purchase Agreement between Corgenix
         Medical Corporation and Barron Partners L.P., dated
         December 28, 2005.
10.2*    Escrow Agreement between Corgenix Medical Corporation,
         Barron Partners LP and Epstein, becker & Green, P.C.,
         dated December 28, 2005.
10.3*    Registration Rights Agreement between Corgenix Medical
         Corporation and Barron Partners L.P., dated December 28,
         2005.
10.4*    Common Stock Purchase Warrant "A" issued to Barron
         Partners.
10.5*    Common Stock Purchase Warrant "B" issued to Barron
         Partners.
10.6*    Common Stock Purchase Warrant "C" issued to Barron
         Partners.
10.7*    Common Stock Purchase Warrant #118 issued to Ascendiant
         Securities, L.L.C.
10.8*    Common Stock Purchase Warrant #119 issued to Ascendiant
         Securities, L.L.C.
10.9*    Common Stock Purchase Warrant #120 issued to Ascendiant
         Securities, L.L.C.
31.1*    Certification of Chief Executive Officer pursuant to
         section 302 of the Sarbanes-Oxley Act.
31.2*    Certification of Chief  Financial Officer pursuant to
         section 302 of the Sarbanes-Oxley Act..
32.1*    Certification by Chief Executive Officer and Chief Financial Officer
         pursuant to 18 U.S.C. Section 1350, or adopted pursuant to Section 906
         of the Sarbanes-Oxley Act of 2002.
*  Filed herewith.
---------------------------------------
(b)          Reports on Form 8-K.

1.           Form 8-K filed September 23, 2005 Results of Operation and
             Financial Condition.
2.           Form 8-K filed September 30, 2005 Departure of Directors or
             Principal Officers; Election of Directors; Appointment of Principal
             Officers
3.           Form 8-K filed December 13, 2005 Regulation FD Disclosure 4. Form
             8-K filed December 29-, 2005 Entry Into Material Definitive
             Agreements
5.           Form 8-K filed January 6, 2006 Departure of Directors or Principal
             Officers; Election of Directors; Appointment of Principal Officers






























                                                                    Exhibit 31.1

                                  CERTIFICATION

I, Douglass T. Simpson, President and Chief Executive Officer, certify that:

1.         I have reviewed this quarterly report on Form 10-QSB of Corgenix
           Medical Corporation.

2.         Based on my knowledge, this quarterly report does not contain any
           untrue statement of a material fact or omit to state a material fact
           necessary to make the statements made, in light of the circumstances
           under which such statements were made, not misleading with respect to
           the period covered by this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           and internal control over financial reporting (as defined in Exchange
           Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
           have:

(a)        Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this report is being prepared;
(b)        Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
(c)        Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of a quarterly
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

(a)        All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
(b)        Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.


   Date:  February 14, 2006

       /S/Douglass T. Simpson
       President and Chief Executive Officer


<PAGE>




                                                                    Exhibit 31.2
                                  CERTIFICATION


I, William H. Critchfield, Senior Vice President and Chief Financial Officer
certify that:

1.         I have reviewed this quartely report on Form 10-QSB of Corgenix
           Medical Corporation.

2.         Based on my knowledge, this quarterly report does not contain any
           untrue statement of a material fact or omit to state a material fact
           necessary to make the statements made, in light of the circumstances
           under which such statements were made, not misleading with respect to
           the period covered by this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           and internal control over financial reporting (as defined in Exchange
           Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
           have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of a quarterly
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.


   Date:  February 14, 2006
       /S/William H. Critchfield
       Senior Vice President and Chief Financial Officer


<PAGE>






                                                                   Exhibit 32.1

                                  CERTIFICATION
             PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
       SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                                 UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of Title 18, United States Code), the
undersigned officers of Corgenix Medical Corporation, a Nevada corporation (the
"Company"), does hereby certify with respect to the Quartely Report of the
Company on Form 10-QSB for the quarter ended September 30, 2005 as filed with
the Securities an Exchange Commission (the "10-QSB Report") that:

i.              the 10-QSB Report fully complies with the requirements of
                section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                and

ii.             the information contained in the 10-QSB Report fairly presents,
                in all material respects, the financial condition and results of
                operations of the Company.


           Dated:    February 14, 2006

      This Certification is made solely for purposes of 18 U.S.C. Section 1350,
      subject to the knowledge standard contained therein, and not for any other
      purpose.

      A signed original of this written statement required by Section 906 of the
      Sarbanes-Oxley Act has been provided to the Company and will be retained
      by the Company and furnished to the Securities and Exchange Commission or
      its staff upon request. This written statement shall not be deemed to be
      "filed" as part of the quarterly report on Form 10-QSB that it
      accompanies.

/S/Douglass T. Simpson
President and Chief Executive Officer


/S/William H. Critchfield
Senior Vice President and Chief Financial Officer






<page>

                                   SIGNATURES


      In accordance with the requirements of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                    CORGENIX MEDICAL CORPORATION



February 14, 2006                     By:   /s/ Douglass T. Simpson
                                           -------------------------
                                           Douglass T. Simpson
                                        President and Chief Executive Officer